TREATMENT OF METASTATIC MELANOMA

The reign of DTIC  (Temodar) is over.
Move to Ipilimumab (Yervoy) AND
In BRAF setting, to Vemurafenib (Zelboraf)

The story of Tremolimumab is somewhat confused.  It did not do better than Chemotherapy BUT WHEN IT WORKS, THE DURATION OF THE WORK IS 3 TIMES THAT OF CHEMOTHERAPY SUGGESTING THAT IN CERTAIN SUBSET, IT IS THE DRUG OF CHOICE.  NOW IF YOU ASK ME WHICH SUBSET, I WILL GO INTO HIDING!
Before I run though let me remind you that Tremelimumab is cytotoxic T cell lymphocyte-associated -antigen-4 blocking monoclonal antibody.  AND REMEMBER T CELL PENETRATE MUCOSA, THEREFORE SIDE EFFECTS WILL BE RASH, DIARRHEA.  7 DEATHS IN TREMELIMUMAB VS 1 DEATH IN CHEMOTHERAPY.   WEIGH YOUR RISKS!